In diabetic patients with overt nephropathy, those taking amlodipine have fewer strokes and myocardial infarctions, and those taking irbesartan have a lower rate of congestive heart failure, but the two have comparable composite cardiovascular event rates.
Dr. Tomas Berl, speaking for the Collaborative Study Group at the University of Colorado, in Denver, Colorado, and Rush Medical Center, in Chicago, Illinois, United States, presented results of a prospective, double-blind, placebo-controlled comparison of cardiovascular events in diabetic patients here November 1 at the 35th Annual Meeting of the American Society of Nephrology.
Mean follow-up time was 2.6 years, and composite cardiovascular outcome was time to cardiovascular death, nonfatal myocardial infarction, congestive heart failure, stroke, coronary and peripheral revascularisation and amputations. The researchers enrolled 1,715 hypertensive adults with serum creatinine 1.0 to 3.0 mg percent in women, 1.2 mg percent and 3.0 mg percent in men, and urinary protein excretion at least 900 mg/24 hours.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!